LinkedIn Corporation (LNKD) was reiterated a ‘Buy’ by UBS analysts on Friday. The broker also raised its price target on the stock to $175 from $170. Mizuho Securities is another firm raising this morning LNKD’s price target to $145 from $127, noting member count in Q116 reached 433 million with 19 million net adds – the highest in two years. LinkedIn also boosted its full-year outlook, in contrast to the disappointing guidance it gave in February. For the second quarter too, LinkedIn issued an encouraging revenue and eps outlook, forecasting adjusted earnings of $0.74 – $0.77 versus consensus of $0.71 per share. The company also issued revenue projection of $885 – $890 million, compared to the consensus revenue estimate of $887.27 million.
So far this morning, LNKD stock is indicated up 3.39% at $127.18.
Amazon.com, Inc. (AMZN) was reiterated as ‘Outperform’ with a $775 from $700 price target on Friday by Wedbush. AMZN stock was also raised this morning to $810 from $685; to $888 from $775; and to $811 from $797 at Mizuho, Stifel, and Axiom Capital, respectively.
Amazon.com recently traded at $660.92, a gain of $58.92 over Thursday’s closing price. The name has a current market cap of $311.69 billion.
NXP Semiconductors NV (NXPI) rating of ‘Buy’ was reiterated today at Jefferies with a price target increase of $130 from $112 (versus a $85.87 previous close).
Shares have traded today between $83.64 and $86.42 with the price of the stock fluctuating between $61.61 to $114.00 over the last 52 weeks.
NXP Semiconductors N.V. shares are currently changing hands at 13.85x this year’s forecasted earnings, compared to the industry’s 13.74x earnings multiple. Ticker has a t-12 price/sales ratio of 3.54. EPS for the same period registers at $6.10.
Shares of NXPI have lost $1.37 to $84.50 in morning trading on Friday, giving it a market cap of roughly $29 billion. The stock traded as high as $114.00 on June 1, 2015.
Celgene Corporation (CELG) was reiterated as ‘Buy’ with a price target increase of $147 from $145 at Sun Trust Rbsn Humphrey. The firm said it views CELG shares as attractive.
Celgene Corp., currently valued at $82.15 billion, has a median Street price target of $135 with a high target of $163. In the past 52 weeks, shares of Summit, New Jersey-based biotech have traded between a low of $92.98 and a high of $140.72, with the 50-day MA and 200-day MA located at $103.61 and $108.74 levels, respectively. Additionally, shares of CELG trade at a P/E ratio of 0.84 and have a Relative Strength Index (RSI) and MACD indicator of 49.38 and -0.62, respectively.
Celgene currently prints a one year loss of 4.57% and a year-to-date loss of around 10%.